NSD2-mediated metabolic reprogramming confers resistance to tamoxifen, an anti-estrogen [137], and treatment with DZNep, an indirect inhibitor of methyltransferases, induces NSD2 degradation, thus restoring tamoxifen sensitivity in breast cancer [155]. Here, NSD2 is linked to breast carcinoma.